These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 27862475)
1. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Sköld CM; Bendstrup E; Myllärniemi M; Gudmundsson G; Sjåheim T; Hilberg O; Altraja A; Kaarteenaho R; Ferrara G J Intern Med; 2017 Feb; 281(2):149-166. PubMed ID: 27862475 [TBL] [Abstract][Full Text] [Related]
2. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis. Sathiyamoorthy G; Sehgal S; Ashton RW South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896 [TBL] [Abstract][Full Text] [Related]
3. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient? Hayton C; Chaudhuri N Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727 [TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic targets in idiopathic pulmonary fibrosis. Kolb M; Bonella F; Wollin L Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. Delanote I; Wuyts WA; Yserbyt J; Verbeken EK; Verleden GM; Vos R BMC Pulm Med; 2016 Nov; 16(1):156. PubMed ID: 27863518 [TBL] [Abstract][Full Text] [Related]
7. Idiopathic pulmonary fibrosis: the turning point is now! Funke M; Geiser T Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356 [TBL] [Abstract][Full Text] [Related]
8. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628 [TBL] [Abstract][Full Text] [Related]
9. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Raghu G Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545 [TBL] [Abstract][Full Text] [Related]
10. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. George PM; Wells AU Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906 [TBL] [Abstract][Full Text] [Related]
11. [Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]. Behr J Dtsch Med Wochenschr; 2012 Mar; 137(12):601-4. PubMed ID: 22415624 [TBL] [Abstract][Full Text] [Related]
12. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Hagmeyer L; Treml M; Priegnitz C; Randerath WJ Respiration; 2016; 91(4):327-32. PubMed ID: 27073887 [TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis: pathogenesis and management. Sgalla G; Iovene B; Calvello M; Ori M; Varone F; Richeldi L Respir Res; 2018 Feb; 19(1):32. PubMed ID: 29471816 [TBL] [Abstract][Full Text] [Related]
14. Current and Future Idiopathic Pulmonary Fibrosis Therapy. Richeldi L; Baldi F; Pasciuto G; Macagno F; Panico L Am J Med Sci; 2019 May; 357(5):370-373. PubMed ID: 31010462 [TBL] [Abstract][Full Text] [Related]